貝達藥業(300558.SZ)快速拉昇逼近漲停 年內累漲逾130%
格隆匯11月26日丨在連續4日回調後,貝達藥業(300558.SZ)午後出現快速拉昇走勢,目前股價逼近漲停,暫成交近6億元,最新總市值296億元。該股年內累漲逾130%。根據安排,貝達藥業約2.31億股(佔公司總股本的57.55%)首發原股東限售股在11月7日解禁。公司是一家由海歸博士創辦的,以自主知識產權創新藥物研究與開發為核心,集醫藥研發、生產、營銷於一體的國家級高新技術企業。公司以“市場需求為導向、科學創新為根本,聚焦腫瘤領域,涵蓋大分子,戰略高度合理佈局,高效執行把握先機”為指導理念,圍繞小分子靶向藥、免疫療法和聯合治療三個方向開展研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.